ONCOVALUE is a consortium of cancer institutes and commercial businesses that will work together to implement value-based oncology care to help improve cancer care by enabling and guiding cancer clinics to collect, harmonize and analyze high-quality Real World Data (RWD) in real-time and by developing an AI-based framework for assessing real-life effectiveness of novel cancer therapies in real-time.
On 4-5 March 2025, the ONCOVALUE consortium convened in Copenhagen for the Consortium Meeting, hosted by Rigshospitalet. The meeting served as a strategic forum to assess project progress, align on key developments, and define the next steps toward enhancing the cost-effectiveness and long-term sustainability of cancer care. Each partner provided structured updates on their respective Work Packages, highlighting milestones achieved and upcoming objectives
Representing Ciaotech and Ttopstart, Chandra Gracia Anweta and Nadia Honing participated in person, delivering a comprehensive update and leading discussions on the Key Exploitable Results (KERs). Chiara Zocchi attended online. Their collective contributions ensured alignment with market needs and maximised the impact of the project’s outcomes.
On 4-5 March 2025, the ONCOVALUE consortium convened in Copenhagen for the Consortium Meeting, hosted by Rigshospitalet. The meeting served as a strategic forum to assess project progress, align on key developments, and define the next steps toward enhancing the cost-effectiveness and long-term sustainability of cancer care. Each partner provided structured updates on their respective Work Packages, highlighting milestones achieved and upcoming objectives
Representing Ciaotech and Ttopstart, Chandra Gracia Anweta and Nadia Honing participated in person, delivering a comprehensive update and leading discussions on the Key Exploitable Results (KERs). Chiara Zocchi attended online. Their collective contributions ensured alignment with market needs and maximised the impact of the project’s outcomes.
